Affiliation:
1. Albany College of Pharmacy and Health Sciences , Albany, New York , USA
2. IBM Watson Health , Cambridge, Massachusetts , USA
3. Spero Therapeutics , Cambridge, Massachusetts , USA
Abstract
Abstract
Background
Limited data are available in the United States on the 12-month epidemiology, outpatient (OP) antibiotic treatment patterns, outcomes, and costs associated with complicated urinary tract infections (cUTIs) in adult patients.
Methods
A retrospective observational cohort study of adult patients with incident cUTIs in IBM MarketScan Databases between 2017 and 2019 was performed. Patients were categorized as OP or inpatient (IP) based on initial setting of care for index cUTI and were stratified by age (<65 years vs ≥65 years). OP antibiotic treatment patterns, outcomes, and costs associated with cUTIs among adult patients over a 12-month follow-up period were examined.
Results
During the study period, 95 322 patients met inclusion criteria. Most patients were OPs (84%) and age <65 years (87%). Treatment failure (receipt of new unique OP antibiotic or cUTI-related ED visit/IP admission) occurred in 23% and 34% of OPs aged <65 years and ≥65 years, respectively. Treatment failure was observed in >38% of IPs, irrespective of age. Across both cohorts and age strata, >78% received ≥2 unique OP antibiotics, >34% received ≥4 unique OP antibiotics, >16% received repeat OP antibiotics, and >33% received ≥1 intravenous (IV) OP antibiotics. The mean 12-month cUTI-related total health care costs were $4697 for OPs age <65 years, $8924 for OPs age >65 years, $15 401 for IPs age <65 years, and $17 431 for IPs age ≥65 years.
Conclusions
These findings highlight the substantial 12-month health care burden associated with cUTIs and underscore the need for new outpatient treatment approaches that reduce the persistent or recurrent nature of many cUTIs.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
Reference61 articles.
1. Urinary tract infections: epidemiology, mechanisms of infection and treatment options;Flores-Mireles;Nat Rev Microbiol,2015
2. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden;Foxman;Infect Dis Clin North Am,2014
3. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection;Carreno;Open Forum Infect Dis,2019
4. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017;Critchley;PLoS One,2019
5. Antimicrobial susceptibility and cross-resistance patterns among common complicated urinary tract infections in U.S. hospitals, 2013 to 2018;Zilberberg;Antimicrob Agents Chemother,2020